IQVIA (NYSE:IQV) Given New $276.00 Price Target at Stifel Nicolaus

IQVIA (NYSE:IQV) had its price objective increased by Stifel Nicolaus from $220.00 to $276.00 in a research note issued to investors on Wednesday,Benzinga reports. The firm presently has a “buy” rating on the medical research company’s stock. Stifel Nicolaus’ price objective would indicate a potential upside of 12.00% from the stock’s previous close.

A number of other research analysts have also recently commented on IQV. BMO Capital Markets increased their price target on IQVIA from $210.00 to $270.00 and gave the company an “outperform” rating in a research note on Wednesday. JPMorgan Chase & Co. upped their price target on shares of IQVIA from $225.00 to $285.00 and gave the company an “overweight” rating in a research report on Wednesday. Weiss Ratings upgraded shares of IQVIA from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday, July 15th. HSBC reissued a “buy” rating and issued a $240.00 price objective on shares of IQVIA in a research note on Monday, July 6th. Finally, Mizuho boosted their target price on shares of IQVIA from $215.00 to $230.00 and gave the stock an “outperform” rating in a research report on Monday, July 13th. Thirteen equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $241.88.

IQVIA Stock Up 1.4%

IQV stock traded up $3.49 during mid-day trading on Wednesday, reaching $246.43. The company had a trading volume of 1,319,378 shares, compared to its average volume of 1,812,333. IQVIA has a 52 week low of $154.50 and a 52 week high of $251.36. The company has a debt-to-equity ratio of 2.20, a current ratio of 0.75 and a quick ratio of 0.75. The stock has a 50 day simple moving average of $190.47 and a two-hundred day simple moving average of $186.86. The company has a market capitalization of $41.13 billion, a price-to-earnings ratio of 30.48, a PEG ratio of 1.91 and a beta of 1.20.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Tuesday, July 28th. The medical research company reported $3.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.03 by $0.12. The business had revenue of $4.37 billion during the quarter, compared to the consensus estimate of $4.30 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.The company’s quarterly revenue was up 8.7% on a year-over-year basis. During the same quarter last year, the firm posted $2.81 EPS. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. As a group, equities analysts predict that IQVIA will post 11.57 earnings per share for the current fiscal year.

IQVIA declared that its Board of Directors has approved a stock buyback plan on Thursday, May 7th that permits the company to repurchase $2.00 billion in shares. This repurchase authorization permits the medical research company to repurchase up to 6.8% of its shares through open market purchases. Shares repurchase plans are often an indication that the company’s board of directors believes its shares are undervalued.

Hedge Funds Weigh In On IQVIA

Hedge funds and other institutional investors have recently modified their holdings of the company. Vanguard Group Inc. grew its stake in shares of IQVIA by 0.8% during the fourth quarter. Vanguard Group Inc. now owns 19,650,532 shares of the medical research company’s stock valued at $4,429,426,000 after buying an additional 159,899 shares during the last quarter. Geode Capital Management LLC boosted its holdings in IQVIA by 0.6% in the fourth quarter. Geode Capital Management LLC now owns 4,374,971 shares of the medical research company’s stock valued at $982,272,000 after acquiring an additional 24,453 shares in the last quarter. Boston Partners raised its stake in IQVIA by 14.9% in the fourth quarter. Boston Partners now owns 4,087,380 shares of the medical research company’s stock worth $923,276,000 after buying an additional 530,672 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in shares of IQVIA by 16.2% in the 4th quarter. JPMorgan Chase & Co. now owns 3,799,600 shares of the medical research company’s stock valued at $856,468,000 after purchasing an additional 528,753 shares during the period. Finally, Invesco Ltd. boosted its holdings in shares of IQVIA by 15.3% during the 3rd quarter. Invesco Ltd. now owns 2,773,984 shares of the medical research company’s stock valued at $526,891,000 after buying an additional 367,204 shares in the last quarter. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

IQVIA News Summary

Here are the key news stories impacting IQVIA this week:

• Positive Sentiment: IQVIA reported second-quarter adjusted earnings of $3.15 per share, ahead of the roughly $3.02–$3.03 analyst consensus, while revenue rose 8.7% year over year to $4.37 billion, exceeding expectations of approximately $4.30 billion. IQVIA Reports Second-Quarter 2026 Results
• Positive Sentiment: The company raised its FY 2026 adjusted EPS guidance to $12.80–$13.00, above the prior consensus of $12.57, and provided revenue guidance of $17.3–$17.5 billion. Management cited broad-based growth, strong clinical-research demand and record R&D bookings. IQV Q2 Earnings Beat Estimates on R&D Bookings, Guidance Raised
• Positive Sentiment: Analyst sentiment strengthened following the report. Robert W. Baird raised its price target from $252 to $287 and maintained an “outperform” rating, implying additional upside based on the cited share price. Baird Raises IQVIA Price Target
• Neutral Sentiment: IQVIA’s earnings beat and guidance increase have put fair value and valuation back in focus. The stock is trading near its 52-week high, with a reported P/E ratio around 30, so continued gains may depend on the company sustaining its growth and bookings momentum. IQVIA Holdings Earnings Beat Keeps Fair Value in Focus

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.